These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11413853)

  • 21. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.
    Lu CL; Lin YH; Wong WW; Lin HH; Ho MW; Wang NC; Hsieh SM; Sheng WH; Hung CC; Chen MY
    J Microbiol Immunol Infect; 2011 Aug; 44(4):258-64. PubMed ID: 21524961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse drug reactions to protease inhibitors.
    Manchanda T; Schiedel D; Fischer D; Dekaban GA; Rieder MJ
    Can J Clin Pharmacol; 2002; 9(3):137-46. PubMed ID: 12422251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment.
    Penzak SR; Chuck SK
    Scand J Infect Dis; 2000; 32(2):111-23. PubMed ID: 10826894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of HIV protease inhibitors on carbohydrate and lipid metabolism.
    Lee GA; Rao MN; Grunfeld C
    Curr HIV/AIDS Rep; 2005 Feb; 2(1):39-50. PubMed ID: 16091248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients.
    Walli R; Herfort O; Michl GM; Demant T; Jäger H; Dieterle C; Bogner JR; Landgraf R; Goebel FD
    AIDS; 1998 Oct; 12(15):F167-73. PubMed ID: 9814858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.
    Carr A; Samaras K; Thorisdottir A; Kaufmann GR; Chisholm DJ; Cooper DA
    Lancet; 1999 Jun; 353(9170):2093-9. PubMed ID: 10382692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of HIV protease inhibitor therapy on lipid metabolism.
    Hui DY
    Prog Lipid Res; 2003 Mar; 42(2):81-92. PubMed ID: 12547652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.
    Lainka E; Oezbek S; Falck M; Ndagijimana J; Niehues T
    Pediatrics; 2002 Nov; 110(5):e56. PubMed ID: 12415062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy.
    Yanovski JA; Miller KD; Kino T; Friedman TC; Chrousos GP; Tsigos C; Falloon J
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1925-31. PubMed ID: 10372688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Racial differences in serum lipids in HIV+ women treated with protease inhibitor regimens.
    Bausserman LL; Tashima KT; DiSpigno M; Maceroni D; Carpenter CC
    HIV Clin Trials; 2004; 5(6):399-405. PubMed ID: 15682353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
    Chang ES; Tetreault DD; Liu YT; Beall GN
    J Am Diet Assoc; 2001 Jun; 101(6):687-9. PubMed ID: 11424549
    [No Abstract]   [Full Text] [Related]  

  • 32. Lipid evaluation in HIV-1-positive patients treated with protease inhibitors.
    Schmidt HH; Behrens G; Genschel J; Stoll M; Dejam A; Haas R; Manns MP; Schmidt RE
    Antivir Ther; 1999; 4(3):163-70. PubMed ID: 12731756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperlipidemia in HIV-positive patients receiving antiretrovirals.
    Segarra-Newnham M
    Ann Pharmacother; 2002 Apr; 36(4):592-5. PubMed ID: 11918504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.
    Rakotoambinina B; Médioni J; Rabian C; Jubault V; Jais JP; Viard JP
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):443-9. PubMed ID: 11511820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy.
    Hatano H; Miller KD; Yoder CP; Yanovski JA; Sebring NG; Jones EC; Davey RT
    AIDS; 2000 Sep; 14(13):1935-42. PubMed ID: 10997397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings.
    Matoga MM; Hosseinipour MC; Aga E; Ribaudo HJ; Kumarasamy N; Bartlett J; Hughes MD;
    Antivir Ther; 2017; 22(3):205-213. PubMed ID: 27740537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ApoE genotype and protease-inhibitor-associated hyperlipidaemia.
    Behrens G; Schmidt HH; Stoll M; Schmidt RE
    Lancet; 1999 Jul; 354(9172):76. PubMed ID: 10406396
    [No Abstract]   [Full Text] [Related]  

  • 38. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
    Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance.
    Worm D; Kirk O; Andersen O; Vinten J; Gerstoft J; Katzenstein TL; Nielsen H; Pedersen C
    HIV Med; 2002 Oct; 3(4):239-46. PubMed ID: 12444941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Lipid profile for treatment with protease inhibitors].
    Livrozet JM
    Med Mal Infect; 2006 Jul; 36 Suppl 2():S212-7. PubMed ID: 17075999
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.